Nifty
:
11966.60
Sensex
:
40894.38
-79.20 (-0.66%)
-161.31 (-0.39%)
Nifty
Sensex
:
:
11966.60
40894.38
-79.20 (-0.66%)
-161.31 (-0.39%)

Strides Pharma Science Ltd.

Pharmaceuticals & Drugs

Rating :
59/99

BSE: 532531 | NSE: STAR

NSE BSE
487.90
18-Feb-2020
  • Open
  • High
  • Low
  • Previous Close
  •  504.60
  •  504.60
  •  483.00
  •  506.05
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  483193
  •  2360.58
  •  547.65
  •  288.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 4,369.45
  • 15.18
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 7,074.27
  • 0.61%
  • 1.61

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 31.28%
  • 0.00%
  • 13.15%
  • FII
  • DII
  • Others
  • 27.16%
  • 16.31%
  • 12.10%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 20.29
  • -7.67

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 14.48
  • -2.73

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 198.64
  • -2.26

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 7.62
  • 22.35
  • 10.56

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.05
  • 3.18
  • 2.05

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 22.64
  • 16.77
  • 13.54

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 19
Dec 18
Var%
Sep 19
Sep 18
Var%
Jun 19
Jun 18
Var%
Mar 19
Mar 18
Var%
Net Sales
732.44
794.50
-7.81%
715.09
519.61
37.62%
685.80
472.69
45.08%
839.70
669.89
25.35%
Expenses
551.60
667.41
-17.35%
568.50
475.63
19.53%
564.88
429.89
31.40%
680.97
577.63
17.89%
EBITDA
180.84
127.09
42.29%
146.59
43.98
233.31%
120.92
42.80
182.52%
158.73
92.26
72.05%
EBIDTM
24.69%
16.00%
20.50%
8.46%
17.63%
9.05%
18.90%
13.77%
Other Income
13.65
0.83
1,544.58%
14.07
9.85
42.84%
10.25
6.47
58.42%
14.78
16.06
-7.97%
Interest
39.63
50.09
-20.88%
40.42
17.28
133.91%
35.34
16.75
110.99%
62.65
45.47
37.78%
Depreciation
43.47
40.67
6.88%
42.00
30.86
36.10%
42.89
29.01
47.85%
43.82
44.34
-1.17%
PBT
127.02
37.90
235.15%
161.68
0.70
22,997.14%
46.29
0.56
8,166.07%
76.01
-3.14
-
Tax
11.30
6.33
78.52%
7.38
-5.54
-
3.12
-13.53
-
11.05
-4.96
-
PAT
115.72
31.57
266.55%
154.30
6.24
2,372.76%
43.17
14.09
206.39%
64.96
1.82
3,469.23%
PATM
15.80%
3.97%
21.58%
1.20%
6.29%
2.98%
7.74%
0.27%
EPS
10.48
32.77
-68.02%
15.97
-1.34
-
0.41
-0.48
-
5.31
63.65
-91.66%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Dec 12
Dec 11
Dec 10
Dec 09
Net Sales
2,973.03
3,011.68
3,344.37
3,826.22
2,862.19
1,195.85
1,340.96
961.76
2,550.04
1,695.84
1,304.77
Net Sales Growth
21.02%
-9.95%
-12.59%
33.68%
139.34%
-10.82%
39.43%
-62.28%
50.37%
29.97%
 
Cost Of Goods Sold
1,266.43
1,466.00
1,378.84
1,281.17
1,502.29
560.49
714.67
491.82
1,264.39
805.65
700.90
Gross Profit
1,706.60
1,545.67
1,965.53
2,545.05
1,359.90
635.37
626.30
469.94
1,285.66
890.19
603.86
GP Margin
57.40%
51.32%
58.77%
66.52%
47.51%
53.13%
46.71%
48.86%
50.42%
52.49%
46.28%
Total Expenditure
2,365.95
2,561.63
3,108.66
3,309.30
2,481.62
967.00
1,117.54
861.18
2,059.36
1,369.22
1,117.84
Power & Fuel Cost
-
54.67
51.33
33.87
77.18
16.02
18.56
12.84
54.24
30.23
24.58
% Of Sales
-
1.82%
1.53%
0.89%
2.70%
1.34%
1.38%
1.34%
2.13%
1.78%
1.88%
Employee Cost
-
442.58
434.05
419.16
357.69
172.06
157.18
120.30
302.74
219.57
177.01
% Of Sales
-
14.70%
12.98%
10.95%
12.50%
14.39%
11.72%
12.51%
11.87%
12.95%
13.57%
Manufacturing Exp.
-
119.16
115.97
137.47
119.23
41.37
35.76
44.43
89.60
63.83
45.15
% Of Sales
-
3.96%
3.47%
3.59%
4.17%
3.46%
2.67%
4.62%
3.51%
3.76%
3.46%
General & Admin Exp.
-
206.67
194.38
172.63
198.71
86.25
66.37
58.16
182.12
159.16
86.87
% Of Sales
-
6.86%
5.81%
4.51%
6.94%
7.21%
4.95%
6.05%
7.14%
9.39%
6.66%
Selling & Distn. Exp.
-
173.21
208.85
161.12
129.57
61.37
66.67
39.94
116.07
88.02
73.40
% Of Sales
-
5.75%
6.24%
4.21%
4.53%
5.13%
4.97%
4.15%
4.55%
5.19%
5.63%
Miscellaneous Exp.
-
99.34
725.25
1,103.88
96.95
29.44
58.33
93.69
50.21
2.76
73.40
% Of Sales
-
3.30%
21.69%
28.85%
3.39%
2.46%
4.35%
9.74%
1.97%
0.16%
0.76%
EBITDA
607.08
450.05
235.71
516.92
380.57
228.85
223.42
100.58
490.68
326.62
186.93
EBITDA Margin
20.42%
14.94%
7.05%
13.51%
13.30%
19.14%
16.66%
10.46%
19.24%
19.26%
14.33%
Other Income
52.75
322.44
920.64
398.08
102.37
38.57
60.23
34.20
31.67
69.70
23.57
Interest
178.04
205.34
196.24
183.10
168.17
47.44
108.88
79.45
194.83
146.65
75.91
Depreciation
172.18
171.85
193.93
198.69
131.25
64.03
56.48
30.86
104.30
63.90
49.19
PBT
411.00
395.30
766.17
533.20
183.50
155.95
118.30
24.48
223.22
185.77
85.41
Tax
32.85
14.49
21.41
51.19
42.45
147.60
40.86
11.15
38.68
45.19
21.90
Tax Rate
7.99%
3.69%
2.96%
10.30%
29.87%
99.35%
44.53%
1.54%
14.18%
24.25%
15.32%
PAT
378.15
372.93
681.31
399.38
113.21
1.57
50.89
712.39
224.48
122.45
109.68
PAT before Minority Interest
384.12
378.19
701.18
445.58
99.68
0.98
50.89
713.44
234.01
141.18
121.04
Minority Interest
5.97
-5.26
-19.87
-46.20
13.53
0.59
0.00
-1.05
-9.53
-18.73
-11.36
PAT Margin
12.72%
12.38%
20.37%
10.44%
3.96%
0.13%
3.80%
74.07%
8.80%
7.22%
8.41%
PAT Growth
603.93%
-45.26%
70.59%
252.78%
7,110.83%
-96.91%
-92.86%
217.35%
83.32%
11.64%
 
Unadjusted EPS
32.17
36.25
74.25
44.73
13.14
141.85
298.56
121.47
38.65
26.11
26.49

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Dec 12
Dec 11
Dec 10
Dec 09
Shareholder's Funds
2,648.70
2,463.66
2,748.82
2,657.87
1,144.92
1,006.83
2,026.24
1,371.48
1,282.78
831.07
Share Capital
89.55
89.50
89.42
89.35
59.62
59.57
58.80
58.38
57.74
89.38
Total Reserves
2,551.59
2,365.10
2,650.55
2,562.75
1,084.50
947.06
1,963.94
1,310.34
1,222.95
724.09
Non-Current Liabilities
2,348.41
2,067.29
2,048.67
2,760.03
285.79
306.42
900.59
1,132.57
2,012.89
1,459.17
Secured Loans
1,806.50
1,551.09
1,622.87
2,614.88
250.23
274.29
731.15
1,054.31
1,387.39
778.70
Unsecured Loans
0.06
0.23
14.84
12.13
17.16
1.24
0.00
0.00
622.45
678.17
Long Term Provisions
21.52
16.55
25.19
14.45
6.02
16.56
57.25
66.19
0.00
0.00
Current Liabilities
2,703.27
1,899.30
3,103.87
1,891.98
1,019.94
707.37
1,797.29
2,791.73
923.65
684.15
Trade Payables
894.19
712.07
774.09
775.40
234.41
262.31
463.08
585.04
419.85
445.23
Other Current Liabilities
249.77
129.98
819.08
347.93
502.47
127.27
651.65
1,369.80
305.00
64.64
Short Term Borrowings
1,339.02
944.39
1,393.96
700.48
203.03
224.56
599.89
684.65
0.00
0.00
Short Term Provisions
220.29
112.86
116.73
68.19
80.03
93.23
82.66
152.24
198.80
174.28
Total Liabilities
7,853.33
6,584.90
8,034.86
7,360.09
2,469.36
2,096.29
4,795.97
5,342.24
4,491.79
3,232.89
Net Block
3,567.19
2,903.00
2,909.03
2,678.68
701.36
554.53
3,016.72
3,187.64
2,328.27
1,856.59
Gross Block
4,046.10
3,229.03
3,186.12
2,825.43
1,080.55
907.33
3,514.29
3,644.82
2,626.71
2,080.70
Accumulated Depreciation
478.92
326.03
277.09
146.75
379.19
352.80
497.57
457.19
298.44
224.11
Non Current Assets
4,808.08
4,101.31
4,243.05
3,845.20
1,039.91
787.65
3,383.87
3,711.33
2,521.48
2,282.61
Capital Work in Progress
506.00
620.29
780.18
814.88
171.17
99.47
241.44
285.03
191.46
84.66
Non Current Investment
494.34
350.08
315.66
127.19
68.76
41.80
0.00
0.00
1.76
341.36
Long Term Loans & Adv.
223.69
197.22
222.56
201.83
96.72
90.40
118.75
229.99
0.00
0.00
Other Non Current Assets
16.86
30.72
15.62
22.62
1.91
1.45
6.96
8.67
0.00
0.00
Current Assets
3,045.26
2,483.59
3,791.82
3,514.89
1,429.44
1,308.63
1,410.94
1,625.27
1,960.40
950.29
Current Investments
284.75
311.48
1,279.54
1,213.76
561.29
401.24
0.06
0.00
0.00
0.00
Inventories
870.70
552.02
732.80
613.14
207.68
175.99
442.33
479.93
312.00
233.42
Sundry Debtors
987.18
882.18
995.91
1,032.97
389.96
364.00
483.23
538.44
383.78
420.27
Cash & Bank
516.65
303.33
329.48
311.59
146.88
231.15
165.74
259.73
339.45
91.20
Other Current Assets
385.98
138.84
209.70
245.90
123.64
136.26
319.58
347.17
925.17
205.40
Short Term Loans & Adv.
249.11
295.75
244.39
97.54
54.46
79.06
44.38
91.79
850.18
150.94
Net Current Assets
341.99
584.29
687.95
1,622.91
409.50
601.26
-386.35
-1,166.46
1,036.75
266.14
Total Assets
7,853.34
6,584.90
8,034.87
7,360.09
2,469.35
2,096.28
4,795.98
5,342.23
4,491.80
3,232.90

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Dec 12
Dec 11
Dec 10
Dec 09
Cash From Operating Activity
60.05
187.07
288.14
73.25
83.40
-271.68
134.26
457.10
323.93
89.61
PBT
344.37
705.80
497.14
146.44
992.01
2,889.87
949.49
272.69
186.37
142.94
Adjustment
94.59
-274.51
190.92
345.56
-756.73
-2,775.01
-415.93
113.84
178.94
42.76
Changes in Working Capital
-323.14
-190.66
-341.30
-341.71
-95.91
-260.68
-310.56
128.87
-2.09
-82.37
Cash after chg. in Working capital
115.82
240.63
346.76
150.29
139.37
-145.81
223.00
515.40
363.23
103.33
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-55.76
-53.56
-58.62
-77.04
-55.97
-125.87
-88.75
-58.30
-39.29
-13.72
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-148.49
582.59
-686.69
-2,224.83
51.87
4,077.09
806.54
-656.47
-941.00
-147.64
Net Fixed Assets
-48.49
677.20
-236.66
-535.93
-66.57
-119.10
-38.27
-18.46
-42.91
-26.86
Net Investments
-383.09
747.64
-143.27
-1,478.58
78.09
248.81
-508.54
77.70
653.52
-578.46
Others
283.09
-842.25
-306.76
-210.32
40.35
3,947.38
1,353.35
-715.71
-1,551.61
457.68
Cash from Financing Activity
194.27
-1,015.69
338.21
2,943.94
-421.25
-3,318.53
-990.03
89.36
850.09
91.64
Net Cash Inflow / Outflow
105.83
-246.03
-60.33
792.35
-285.98
486.88
-49.23
-110.01
233.03
33.60
Opening Cash & Equivalents
256.16
515.08
1,110.74
298.91
586.00
132.02
211.93
325.17
79.00
45.88
Closing Cash & Equivalent
365.89
256.16
515.08
1,110.74
298.42
586.00
132.02
212.27
325.17
78.78

Financial Ratios

Consolidated /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Dec 12
Dec 11
Dec 10
Dec 09
Book Value (Rs.)
294.94
274.26
306.41
296.83
191.91
168.99
343.78
233.49
220.07
190.06
ROA
5.24%
9.59%
5.79%
2.03%
0.04%
1.48%
14.07%
4.76%
3.66%
4.36%
ROE
14.84%
27.00%
16.53%
5.25%
0.09%
3.36%
42.16%
17.77%
13.87%
21.45%
ROCE
11.02%
16.07%
10.75%
7.54%
10.92%
7.76%
21.08%
12.82%
11.96%
10.93%
Fixed Asset Turnover
0.83
1.04
1.27
1.47
1.21
0.61
0.27
0.82
0.72
0.80
Receivable days
113.28
102.49
96.77
90.73
114.71
114.80
193.43
65.68
86.42
105.79
Inventory Days
86.21
70.11
64.20
52.34
58.37
83.78
174.61
56.40
58.62
56.75
Payable days
114.64
116.23
117.33
75.51
76.81
112.69
253.28
92.58
119.83
129.46
Cash Conversion Cycle
84.85
56.37
43.64
67.55
96.27
85.89
114.76
29.50
25.22
33.08
Total Debt/Equity
1.22
1.03
1.35
1.34
0.78
0.54
0.79
1.94
1.58
1.79
Interest Cover
2.91
4.68
3.71
1.85
4.13
1.84
10.12
2.40
2.27
2.88

Annual Reports:

FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013
FY 2012
FY 2011
FY 2010

News Update:


  • Strides Pharma’s arm enters into agreement with Pii to acquire 18 ANDAs
    7th Feb 2020, 10:28 AM

    With access to these products, the company will significantly expand its niche offerings on its front end

    Read More
  • Strides Pharma Science gets nod to merge Vivimed Life Sciences with itself
    31st Jan 2020, 09:46 AM

    The consolidation of entities with similar functions within the group, would result in, operational and administrative efficiencies

    Read More
  • Strides Pharma reports 68% fall in Q3 consolidated net profit
    30th Jan 2020, 09:43 AM

    Total consolidated income of the company increased by 28.49% at Rs 744.66 crore for Q3FY20

    Read More
  • USFDA completes inspection at Strides Pharma Science’s Alathur facility
    24th Jan 2020, 15:44 PM

    This is the second consecutive Zero 483 inspection for the site

    Read More
  • Strides Pharma’s arm gets USFDA’s tentative approval for Triamcinolone Acetonide Ointment
    24th Jan 2020, 11:01 AM

    The product will be manufactured at the company’s Oral dosage facility at Bangalore

    Read More
  • Strides Pharma Science’s arm gets EIR from USFDA for Florida facility
    20th Jan 2020, 09:09 AM

    The EIR was issued as an outcome of the USFDA’s inspection of the facility in December 2019

    Read More
  • Strides Pharma’s arm gets USFDA’s approval for Loratadine OTC Softgel Capsules
    16th Jan 2020, 10:18 AM

    The product is a generic version of Claritin Liqui-Gels Capsules, 10 mg, of Bayer HealthCare LLC

    Read More
  • Strides Pharma’s arm gets USFDA’s tentative nod for Diclofenac Potassium Softgel Capsules
    4th Dec 2019, 11:08 AM

    The US market for Diclofenac Potassium Softgel Capsules, 25 mg is approximately $30 million

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.